SR9009

Also sold as Stenabolic, a synthetic REV-ERB agonist studied almost entirely in mice and cell cultures. There are no registered human clinical trials, the only human records are one liver-injury case report and an anti-doping positive, and it is prohibited at all times in tested sport.

Last updated: September 2026

What is SR9009?

SR9009, sold under the name Stenabolic, is a synthetic REV-ERB agonist: a small molecule with the formula C20H24ClN3O4S and a molecular weight of about 438, not a peptide, a protein, or a peptide hormone. It sits in our research library because people search for it alongside peptides, not because it shares their chemistry (PubChem CID 57394020).

You will see SR9009 described as a SARM, and a 2025 case report calls it "a newer SARM" (PMID 40765588). That label is misleading: by structure it is a REV-ERB agonist, and anti-doping authorities classify it as a Hormone and Metabolic Modulator, a different category from true SARMs such as RAD-140. It is marketed like a SARM but is not one by chemistry or by anti-doping class (USADA sanction record, 2024; PubChem CID 57394020).

No source reviewed for this page shows SR9009 approved for human use in any market. A 2016 study notes that "no pharmaceutical preparations are available yet," while describing SR9009 as marketed in illicit products (PMID 27706103). It is also described as widely available to buy online as a "supplement" (PMID 34224639), and the same 2016 group demonstrated SR9009 in a black-market product bought over the internet and called SR9009 and SR9011 "potentially harmful compounds" (PMID 27706103). For endurance-focused comparisons, readers often look at Cardarine (GW-501516).

How It Works

REV-ERB agonism: SR9009 is described as an agonist of the REV-ERB nuclear receptors, which help set the circadian clock. In mice, REV-ERB agonists altered the circadian pattern of core clock gene expression in the hypothalamus and of metabolic genes in liver, skeletal muscle, and fat (animal study, mice, PMID 22460951).

Metabolic gene shifts: the same 2012 work reported changes across metabolic genes that the authors linked to increased energy expenditure in mice. SR9009 is marketed as a performance enhancer, but increased energy expenditure in mice is not a measured human outcome (animal study, mice, PMID 22460951).

The target-validity problem, the most important caveat on this page: several studies find SR9009 still active after its supposed target is removed. It decreased cell viability in cells lacking both REV-ERB proteins (PMID 31127047), kept its cardioprotective effect in mice without cardiac REV-ERB (PMID 35911512), acted through LXRalpha rather than REV-ERBs against prostate cancer (PMID 36357378), and suppressed mast cells even with a core clock gene mutated (PMID 31847374). In plain terms, effects credited to SR9009 appear in animals and cells that have had the drug's supposed target deleted, so what it actually does in a living body is unsettled.

Metabolism and interactions, in vitro only: human liver microsome studies found SR9009 broken down by CYP3A4, CYP3A5, CYP2C19, and CYP2D6, with interaction signals alongside drugs such as ketoconazole, fluoxetine, and paroxetine. These are test tube findings, not human dosing data (in vitro, human liver microsomes, PMID 30395700).

Sleep and wake: in mice, REV-ERB agonists shift sleep architecture and induce wakefulness during the light phase, and that wake effect required REV-ERBbeta (animal study, mice, PMID 27603791, PMID 29355503).

Effects Reported in Animal and Cell Studies

In diet-induced obese mice, a REV-ERB agonist reduced fat mass and improved dyslipidaemia and hyperglycaemia, with gene changes the authors linked to increased energy expenditure. The 2012 abstract describes "a REV-ERB agonist," not SR9009 by name, in that sentence (animal study, mice, route not stated, PMID 22460951).
Chronic low-dose SR9009 reduced weight gain, insulin resistance, and white fat mass in mice exposed to constant light, though the authors reported "no significant impact on overall energy homeostasis" and noted the effects "remain limited at low doses" (animal study, mice, route not stated, PMID 39800061).
SR9009 improved exercise tolerance in normal mice, appearing as the comparator in a study whose main subjects were synthetic SR9009 analogues (animal study, mice, route not stated, PMID 39059249).
Two REV-ERB agonists, SR9009 and SR9011, impaired glioblastoma growth in vivo and improved survival "without causing overt toxicity in mice" (animal study, mice, route not stated, PMID 29320480).
SR9009 was lethal to prostate cancer cell lines and restrained tumour growth in xenografts, but the effect ran through LXRalpha rather than REV-ERBs (in vitro and xenograft, host species not stated, PMID 36357378).
SR9009 improved heart function after pressure overload in mice, yet the benefit persisted in mice lacking cardiac REV-ERB, so it did not depend on the supposed target (animal study, mice, route not stated, PMID 35911512).

Doses Used in Animal Studies

Phase	Dose	Frequency	Duration
Human use	No established human dose	No registered human clinical trial (ClinicalTrials.gov returned 0 studies)	Not established
Animal study: spinal cord injury (mice)	100 mg/kg per day (animal study, mice, intraperitoneal, PMID 41232745)	Two 50 mg/kg doses at ZT1 and ZT12 (animal study, mice, intraperitoneal, PMID 41232745)	7 days of dosing, 6 weeks of follow-up (n not stated in the abstract)
Animal study: constant-light metabolic model (mice)	10 mg/kg daily (animal study, mice, route not stated, PMID 39800061)	Daily, described by the authors as low-dose	8 weeks (n not stated in the abstract)

These are the only two numeric doses stated in the abstracts reviewed for this page, both in mice. They are educational, not a recommendation or a human protocol. Milligram per kilogram figures in animals cannot be converted or scaled to a person, and no human dose is established. Any decision to use a compound belongs with a licensed prescriber.

Side Effects

Reported in the human record

⚠Hepatocellular liver injury in a single case report: a 40-year-old man developed drug-induced liver injury after starting Stenabolic, which the treating doctors judged the likely cause after excluding infection and autoimmune causes, concluding that its use "should be discouraged" (case report, n=1, human, PMID 40765588).
⚠No human adverse event rate, maximum tolerated dose, or organ toxicity screen has been reported for SR9009 in the sources reviewed, so the true human side effect profile is simply unknown (no human safety data).

Reported in animal and cell studies

•Wakefulness during the light phase, when mice normally sleep, reported as a pharmacological effect in mice (animal study, mice, PMID 27603791).
•Decreased cell viability even in cells with both REV-ERB proteins deleted, a marker of off-target activity (in vitro, PMID 31127047).
•A 2016 analytical study describes SR9009 and SR9011 as "potentially harmful compounds" and recommends screening for them in doping control (in vitro and analytical, PMID 27706103).

Who Should NOT Use SR9009

✕Athletes and anyone subject to anti-doping testing: SR9009 is a non-specified substance in the class of Hormone and Metabolic Modulators and is prohibited at all times under the World Anti-Doping Code, as adopted by USADA and World Athletics. An eight-year sanction has been issued in a case involving SR9009 metabolites (USADA sanction record, 2024).
✕Anyone expecting a proven or approved human treatment: there is no registered human clinical trial, ClinicalTrials.gov returned zero studies, and no source reviewed here shows SR9009 approved for human use in any market.
✕Context, at the class level and not specific to SR9009: the FDA warns that SARMs as a class are unapproved drugs linked to serious harms including liver injury. SR9009 is sold as a SARM but is a REV-ERB agonist by structure and sits in a different anti-doping class, so this is included as context, not as a finding about SR9009 (FDA consumer update).

What the Research Does and Does Not Show

In people

No registered clinical trial and no interventional study, so there is no evidence base to predict what SR9009 does in a person. The only human records are one liver-injury case report and an anti-doping positive (ClinicalTrials.gov returned 0 studies; PMID 40765588).

In animals

Metabolic and exercise effects have been reported in mice, at milligram per kilogram doses and by routes that do not translate to people, and several effects persist when the drug's supposed target is deleted (PMID 22460951, PMID 39059249, PMID 39800061, PMID 31127047).

Over time

No human safety follow-up exists. In one mouse spinal cord study, early tissue markers improved but hindlimb recovery and tissue sparing were no different by six weeks (PMID 41232745).

In sport

SR9009 and its metabolites can be detected in anti-doping testing, and a real eight-year sanction has been issued in a case involving them (USADA sanction record, 2024).

Notes from Ho Chi Minh City

SR9009 gets marketed as a performance enhancer for people chasing an endurance edge, but the honest picture is a lot narrower than that marketing suggests. It is not on the shelf at Long Châu, where a search returns nothing, it is banned at all times in tested sport, and the only human medical record anyone can actually point to is a single case of liver injury serious enough that the treating doctors wrote that its use should be discouraged. Everything measurable sits in mice and cell dishes, and even there the compound keeps producing effects after its supposed target has been deleted, which is not a reassuring property in something people are taking. Whether to use a compound at all, and by what route, is a decision for a licensed prescriber, not a forum thread.

Sourcing in Vietnam

This page could verify only one licensed Vietnamese pharmacy, Nhà thuốc Long Châu, which lists no SR9009 product: a search returns nothing for either "SR9009" or "Stenabolic," and a control search for a common medicine on the same site does return products, so the empty result reflects Long Châu's catalogue rather than a fetching error. Pharmacity, Nhà thuốc An Khang, and the national drug registry could not be read from here, so this page makes no claim either way about them, and no price is quoted because no licensed listing was found. In the research literature SR9009 is described as widely sold online as a "supplement" and demonstrated in a black-market product bought over the internet, which is not the same as an approved pharmaceutical preparation; the 2016 literature reports that no pharmaceutical preparations are available (PMID 27706103).

FAQ

Q: Is SR9009 a peptide?

A: No. SR9009 is a small-molecule REV-ERB agonist with the formula C20H24ClN3O4S and a molecular weight of about 438. It has no amino acids and no peptide bonds, so it is not a peptide, a protein, or a peptide hormone. It appears in this library only because people search for it alongside peptides.

Q: Is SR9009 a SARM?

A: It is often sold and sometimes described as a SARM, and a 2025 case report calls it "a newer SARM." By structure it is a REV-ERB agonist, and anti-doping authorities place it in Hormone and Metabolic Modulators, a different class from true SARMs such as RAD-140. So it is marketed like a SARM but is not classified as one.

Q: Are there any human clinical trials of SR9009?

A: No. ClinicalTrials.gov returns zero studies for SR9009, Stenabolic, and SR-9009, and a PubMed triage of the most relevant records found no human interventional study. The only human records are a single liver-injury case report and an anti-doping positive.

Q: Is SR9009 banned in sport?

A: Yes. It was added to the Prohibited List in the 2018 cycle (USADA, 2018 Prohibited List summary) and is prohibited at all times as a non-specified Hormone and Metabolic Modulator under the World Anti-Doping Code. A track and field athlete received an eight-year sanction in a case involving SR9009 metabolites, from an out-of-competition test dated September 2023.

Q: Can you buy SR9009 at a pharmacy in Vietnam?

A: A search of Nhà thuốc Long Châu returns no product for either "SR9009" or "Stenabolic," and a control search for a common medicine on the same site does return products, so that absence is real. Pharmacity, An Khang, and the national drug registry could not be read from here, so this page makes no claim either way about them. No price is shown because no licensed listing was found.

Q: Does SR9009 have poor oral bioavailability?

A: You will see that claim repeated widely, but none of the sources reviewed for this page state an oral bioavailability figure or a half-life for SR9009, so this page does not assert it. No human dose, route, or pharmacokinetic value is established.

Where to Get SR9009 in Vietnam

SR9009 is not listed by Nhà thuốc Long Châu, where an on-site search returns no product. Whether Pharmacity or An Khang stock it could not be verified from here, so no claim is made either way. It is prohibited at all times in tested sport, and no source reviewed here shows it approved for human use. The supply index linked below is a general site resource, offered as information and not as an endorsement of sourcing this compound; no vendor testing or certificate of analysis was gathered for this page.

View Supply Index

Related Peptides

Cardarine (GW-501516)RAD-140 (Testolone)Peptide Library

Research & Sources

Limited effects of the REV-ERB agonist SR9009 after mouse spinal cord contusion: Reduced acute pathology with unaffected functional recovery and chronic white matter loss · Neuroscience Letters (2026) (PMID: 41232745)
Mouse spinal cord contusion model. SR9009 given intraperitoneally at 100 mg/kg per day for 7 days; acute markers improved but functional recovery and white matter sparing did not. n not stated in the abstract.
Chronic low-dose REV-ERBs agonist SR9009 mitigates constant light-induced weight gain and insulin resistance via adipogenesis modulation · Biomedical Journal (2025) (PMID: 39800061)
Mice, constant-light model. Low-dose SR9009 (10 mg/kg daily) for eight weeks; route not stated in the abstract; effects described by the authors as limited at low doses.
Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists · Nature (2012) (PMID: 22460951)
The founding metabolic result in mice. The abstract sentence on fat mass and dyslipidaemia describes "a REV-ERB agonist," not SR9009 by name. No dose is stated in the abstract.
SR9009 has REV-ERB-independent effects on cell proliferation and metabolism · Proceedings of the National Academy of Sciences (2019) (PMID: 31127047)
SR9009 decreased cell viability and altered metabolism in cells lacking both REV-ERB proteins, so its effects cannot be read as a pure surrogate for REV-ERB activity.
SR9009 improves heart function after pressure overload independent of cardiac REV-ERB · Frontiers in Cardiovascular Medicine (2022) (PMID: 35911512)
Cardioprotection against pressure overload in mice persisted in cardiac-specific double knockout mice, indicating a REV-ERB-independent mechanism.
SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRalpha/FOXM1 pathway independently of REV-ERBs · Cell Death & Disease (2022) (PMID: 36357378)
SR9009 was lethal to prostate cancer cell lines and restrained xenograft growth through LXRalpha rather than REV-ERBs. Xenograft host species not stated in the abstract.
The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock · International Journal of Molecular Sciences (2019) (PMID: 31847374)
Mouse mast cell effects observed even after mutation of the core circadian gene Clock, another off-target signal.
Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence · Nature (2018) (PMID: 29320480)
SR9009 and SR9011 impaired glioblastoma growth in vivo and improved survival without overt toxicity in mice. Dose and route not stated in the abstract. This, not PubChem, is the source for any cancer statement, since the PubChem record description conflates SR9009 with SR9011.
Regulation of exercise ability and glycolipid metabolism by synthetic SR9009 analogues as new REV-ERB-alpha agonists · Bioorganic & Medicinal Chemistry (2024) (PMID: 39059249)
Medicinal chemistry study of SR9009 analogues; SR9009 improved exercise tolerance in normal mice as the comparator. Dose and route not stated in the abstract.
Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation · PLoS One (2016) (PMID: 27603791)
In mice, REV-ERB agonists induced wakefulness during the light period, with no tolerance over a three-day once-daily regimen. Dose and route not stated in the abstract.
REV-ERBbeta is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009 · Biochemical Pharmacology (2018) (PMID: 29355503)
REV-ERBbeta-deficient mice given SR9009 failed to show the drug-induced increase in wakefulness.
A further insight into the metabolic profile of the nuclear receptor Rev-erb agonist, SR9009 · Drug Testing and Analysis (2018) (PMID: 30395700)
In vitro human liver microsome study of SR9009 metabolism by CYP isoenzymes, with drug interaction and polymorphism signals. Not a human in vivo study.
In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011 · International Journal of Molecular Sciences (2016) (PMID: 27706103)
Human liver microsome metabolism; SR9009 demonstrated in a black-market product; the authors call the pair "potentially harmful compounds" and note no pharmaceutical preparations are available. In 1511 stored doping samples neither parent nor metabolites were detected as of 2016.
In vitro metabolism of the REV-ERB agonist SR-9009 and subsequent detection of metabolites in associated routine equine plasma and urine doping control samples · Drug Testing and Analysis (2022) (PMID: 34224639)
Describes SR-9009 as widely available to purchase online as "supplement" products, and reports the first adverse analytical finding for SR-9009 in an equine doping sample.
When Gains Go Wrong: A Case of Selective Androgen Receptor Modulator-Related Liver Injury · Cureus (2025) (PMID: 40765588)
Single human case report, n=1: a 40-year-old man with hepatocellular liver injury after starting Stenabolic, who was also taking multiple over-the-counter supplements. The authors conclude such use should be discouraged. This paper, not a pharmacology source, is where the SARM label originates.
PubChem Compound Summary, CID 57394020 (SR9009) · PubChem, National Library of Medicine (2026) Link
Molecular formula C20H24ClN3O4S, molecular weight about 438, CAS 1379686-30-2. Record description: "SR-9009 is a REV-ERB agonist." Accessed 2026-09-06.
ClinicalTrials.gov registry search (SR9009, Stenabolic, SR-9009) · ClinicalTrials.gov, National Library of Medicine (2026) Link
API v2 returned totalCount 0 for each of the three terms on 2026-09-06, a genuine null (HTTP 200 with a well formed body).
2018 Prohibited List: Summary of Major Changes · U.S. Anti-Doping Agency (USADA) (2017) Link
Records that SR9009, a Rev-Erb-alpha agonist, was added as an example of AMP-activated protein kinase activators under S4.5.1. The source renders the classification with a Greek letter; paraphrased here. Accessed 2026-09-06.
Independent Arbitrator Imposes Doping Sanction for Gil Roberts · U.S. Anti-Doping Agency (USADA) (2024) Link
An eight-year sanction after an out-of-competition test on September 20, 2023 that returned SR9009 metabolites among other substances. States SR9009 is a non-specified Hormone and Metabolic Modulator, prohibited at all times.
FDA Warns of Use of Selective Androgen Receptor Modulators (SARMs) Among Teens, Young Adults · U.S. Food and Drug Administration (2026) Link
A statement about the SARM class. The page does not name SR9009, SR-9009, Stenabolic, or REV-ERB; used here only for class-level context. Accessed 2026-09-06.
Nhà thuốc Long Châu on-site product search (SR9009, Stenabolic) · Nhà thuốc Long Châu (2026) Link
Returned 0 products for both spellings on 2026-09-06. A paracetamol control on the same route returned 289 products, so the null is real, not a fetching error.

Important Disclaimer

Educational content only. Not medical advice. SR9009 is a research compound, not a peptide. No source reviewed for this page shows it approved for human use in any market, and it is prohibited at all times in tested sport. A search of Nhà thuốc Long Châu returns no product; other Vietnamese pharmacies could not be verified from here. Consult a licensed physician before any use.